A treatment based on GRO Biosciences‘ ProGly program — which uses specially designed proteins to regulate the immune system — substantially reduced disease activity in an animal model of myasthenia gravis (MG), according to new data presented by the company. “We are greatly encouraged by the results of…
UCB’s zilucoplan and Rystiggo (rozanolixizumab) both were approved in Japan to treat adults with generalized myasthenia gravis (gMG) who lack an adequate response to steroids or other immunosuppressive treatments. “With the approval in Japan of zilucoplan and [Rystiggo], we are very proud and excited to expand our…
Health Canada has approved Vyvgart (efgartigimod alfa-fcab) to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR), the most common target of MG-causing antibodies. The approval is based on positive data from the Phase 3 ADAPT clinical trial (NCT03669588),…
A more severe disease course was seen among pediatric myasthenia gravis (MG) patients with antibodies against acetylcholine receptors (AChRs) who also have antibodies against ryanodine receptors (RyR) and the titin protein, according to a new study. These children had a higher likelihood of having generalized MG (gMG) and…
A 44-year-old woman positive for the human immunodeficiency virus (HIV) developed myasthenia gravis (MG) after receiving treatment with antiretroviral agents. While no clear guidelines exist for treating MG in HIV-infected patients, researchers noted the woman was successfully treated with prednisone, azathioprine, and plasma exchange. According to them, this approach…
A European Medicines Agency (EMA) committee has recommended the approval of Argenx’s under-the-skin, or subcutaneous, formulation of efgartigimod as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChRs). Argenx’s into-the-vein (intravenous) formulation of efgartigimod, sold as Vyvgart,…
Treatment with the experimental therapy povetacicept (ALPN-303) reduced disease activity in a mouse model of myasthenia gravis (MG), according to data shared by its developer, Alpine Immune Sciences. Povetacicept also was tolerated well by healthy volunteers participating in a Phase 1 clinical trial. “Together, these data provide strong…
Recipharm is partnering with Ahead Therapeutics to develop a new type of therapy to reestablish immune tolerance and prevent the self-reactive immune attacks that cause myasthenia gravis (MG). “Together with our partner, we are determined to help them turn hope into reality for people living with myasthenia…
Folia Health is expanding the use of its smartphone app for gathering self-reported patient health data to people with myasthenia gravis (MG) and other neurological conditions. Patients’ daily experiences will contribute to obtaining comprehensive data on disease progression and treatment response, which are expected to contribute to improving…
Elderly people with myasthenia gravis (MG) are at higher risk of experiencing side effects related to disease treatments, which can be fatal for patients in some cases, a new study found. In fact, treatment-related adverse effects were seen among more than 40% of patients in the study —…
Get regular updates to your inbox.
